Skip to main content

Neuroscience Biomarkers and Biosignatures Converging Technologies, Emerging Partnerships: Workshop Summary (2008) / Chapter Skim
Currently Skimming:

Introduction
Pages 9-14

The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.


From page 9...
... Forum on Neuroscience and Nervous System Disorders about the challenges and opportunities in identifying biomarker targets that are not currently being aggressively pursued but that could be developed to practicality within the next 5 years by public-private partnerships. The goal of the workshop was focused consideration of potential biomarker, or biosignature, opportunities, including the current state of biomarker development and the resources needed to carry this effort forward.
Read the entire page →
From page 10...
... are sometimes referred to as a "biosignature." An example of a biosignature would be a composite measure of imaging and genomics that offered improved diagnostic sensitivity and specificity compared to that of either measure alone. The expected value of biomarkers to the pharmaceutical industry is to increase the efficiency of drug development, thereby permitting more drug candidates to be brought forward and perhaps increasing the information gleaned from the trials performed.
Read the entire page →
From page 11...
... Some candidate biomarkers are likely to emerge only from large-scale molecular profiling efforts, whose assembly can require a daunting combination of resources, technology, and access to human subjects, often beyond the capabilities of individual organizations. PUBLIC-PRIVATE PARTNERSHIPS A logical path forward is the formation of public-private research partnerships that bring together academic, government, and industry researchers.
Read the entire page →
From page 12...
... was expressly created by the IOM in 2005 to bring together the public and private sectors, among other key stakeholders, to discuss issues of mutual interest and concern on topics of common and critical importance, particularly ones that stimulate partnerships to accelerate understanding and treatment of nervous system disorders. The Forum is a venue for convening stakeholders, sponsoring workshops, and producing workshop summaries intended to inform both the Forum membership and the general public.
Read the entire page →
From page 13...
... The next two sessions focused specifically on biomarkers for psychiatric diseases and drug addition, and then neurological and eye diseases. The workshop concluded with a roundtable discussion on directions for the future.
Read the entire page →

Key Terms

  • candidate biomarkers
  • aggressively pursued
  • pharmaceutical industry
  • potential biomarker
  • individual pharmaceutical

  • biomarker targets
  • identifying biomarker
  • neuroimaging initiative
  • forum membership
  • producing workshop

  • biomarkers consortium
  • industry research
  • industry researchers
  • specificity compared
  • subjective readouts

  • clinical trials
  • iom forum
  • clinically meaningful
  • disease arenas
  • placebo responses

  • diagnostic sensitivity
  • critical importance
  • expressly created
  • summaries intended
  • aforementioned considerations

  • focused process
  • research partnerships
  • clinical benefit
  • retinal disorders
  • human subjects


    • This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
    More information on Chapter Skim is available.